| NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | NOT_YET_RECRUITING | PHASE1 | 2025-12-31 | 2028-08-18 | 2028-08-18 |
| NCT07124078 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) | NOT_YET_RECRUITING | PHASE2 | 2025-12-15 | 2029-07-31 | 2029-01-31 |
| NCT07213973 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | NOT_YET_RECRUITING | PHASE2 | 2025-12-14 | 2028-03-25 | 2028-03-25 |
| NCT07214779 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | NOT_YET_RECRUITING | PHASE3 | 2025-12-01 | 2029-05-14 | 2028-11-15 |
| NCT07049575 | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | RECRUITING | PHASE1 | 2025-10-15 | 2026-12-09 | 2026-12-09 |
| NCT07104565 | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | NOT_YET_RECRUITING | PHASE2 | 2025-10-15 | 2028-03-09 | 2027-09-23 |
| NCT07008118 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | RECRUITING | PHASE1 | 2025-10-01 | 2029-12-14 | 2028-03-14 |
| NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | RECRUITING | PHASE2 | 2025-09-30 | 2027-10-24 | 2027-04-27 |
| NCT06804811 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | NOT_YET_RECRUITING | PHASE3 | 2025-08-08 | 2027-12-01 | 2027-04-30 |
| NCT07039929 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants | RECRUITING | PHASE1 | 2025-07-28 | 2026-01-03 | 2026-01-03 |
| NCT07018635 | A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants | RECRUITING | PHASE1 | 2025-07-16 | 2025-10-29 | 2025-10-29 |
| NCT06873789 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2025-06-30 | 2028-10-30 | 2028-10-30 |
| NCT06843408 | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | RECRUITING | PHASE1, PHASE2 | 2025-06-25 | 2027-12-31 | 2026-07-03 |
| NCT06959225 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | RECRUITING | PHASE3 | 2025-06-23 | 2027-07-11 | 2026-10-09 |
| NCT06832618 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis | RECRUITING | PHASE3 | 2025-06-17 | 2028-05-18 | 2026-07-13 |
| NCT06958211 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) | RECRUITING | PHASE3 | 2025-06-12 | 2027-07-11 | 2026-10-09 |
| NCT06821542 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy | ACTIVE_NOT_RECRUITING | PHASE3 | 2025-06-04 | 2032-11-30 | 2028-05-31 |
| NCT06941077 | A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants | COMPLETED | PHASE1 | 2025-05-12 | 2025-06-03 | 2025-06-03 |
| NCT06909162 | A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics of INCB123667 When Administered Orally to Healthy Adult Participants | COMPLETED | PHASE1 | 2025-05-05 | 2025-05-27 | 2025-05-16 |
| NCT06615050 | A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) | RECRUITING | PHASE3 | 2025-04-02 | 2031-01-17 | 2031-01-17 |
| NCT06818812 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | ACTIVE_NOT_RECRUITING | PHASE1 | 2025-03-27 | 2027-03-27 | 2027-03-27 |
| NCT06855498 | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | RECRUITING | PHASE3 | 2025-02-28 | 2028-02-28 | 2028-02-28 |
| NCT06775327 | Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants | COMPLETED | PHASE1 | 2025-02-13 | 2025-05-28 | 2025-05-28 |
| NCT06548360 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | RECRUITING | PHASE3 | 2025-01-24 | 2027-03-13 | 2026-08-10 |
| NCT06585774 | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | RECRUITING | PHASE3 | 2025-01-21 | 2030-03-31 | 2027-09-28 |
| NCT06713590 | A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants | COMPLETED | PHASE1 | 2025-01-14 | 2025-06-10 | 2025-06-06 |
| NCT06388564 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | RECRUITING | PHASE2 | 2024-10-11 | 2029-12-01 | 2027-06-01 |
| NCT06516952 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | RECRUITING | PHASE3 | 2024-10-10 | 2027-06-02 | 2026-10-25 |
| NCT06516965 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | RECRUITING | PHASE3 | 2024-10-10 | 2027-06-02 | 2026-09-11 |
| NCT06555081 | A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants | COMPLETED | PHASE1 | 2024-09-25 | 2024-11-07 | 2024-10-25 |
| NCT06505265 | A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants | COMPLETED | PHASE1 | 2024-08-12 | 2024-09-18 | 2024-09-18 |
| NCT06313593 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | RECRUITING | PHASE1 | 2024-08-08 | 2028-03-30 | 2027-03-30 |
| NCT06263478 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-07-30 | 2027-03-30 | 2025-08-06 |
| NCT06441318 | A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants | COMPLETED | PHASE1 | 2024-07-12 | 2024-09-10 | 2024-09-10 |
| NCT06416800 | A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants | COMPLETED | PHASE1 | 2024-06-19 | 2025-01-15 | 2025-01-15 |
| NCT06309394 | A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants | COMPLETED | PHASE1 | 2024-05-15 | 2024-06-04 | 2024-06-04 |
| NCT06380205 | A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females | COMPLETED | PHASE1 | 2024-05-07 | 2024-06-07 | 2024-06-07 |
| NCT06238817 | A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-04-26 | 2025-10-30 | 2025-05-21 |
| NCT05949632 | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2024-04-16 | 2025-06-06 | 2025-06-06 |
| NCT06310304 | A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants. | COMPLETED | PHASE1 | 2024-03-26 | 2024-05-15 | 2024-04-16 |
| NCT06213818 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant | RECRUITING | PHASE1 | 2024-03-14 | 2025-10-06 | 2025-10-06 |
| NCT06213831 | A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream | COMPLETED | PHASE1 | 2024-02-27 | 2025-07-17 | 2025-07-17 |
| NCT06212999 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | RECRUITING | PHASE3 | 2024-01-30 | 2026-12-26 | 2026-12-26 |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | RECRUITING | PHASE1 | 2024-01-04 | 2027-01-01 | 2027-01-01 |
| NCT06039384 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | TERMINATED | PHASE1 | 2023-12-28 | 2025-07-11 | 2025-04-11 |
| NCT06034002 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | RECRUITING | PHASE1 | 2023-12-04 | 2028-10-29 | 2028-10-29 |
| NCT06113445 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-11-29 | 2027-02-24 | 2026-02-25 |
| NCT06113471 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-11-27 | 2027-03-16 | 2026-03-17 |
| NCT05879822 | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-10-30 | 2026-07-22 | 2026-07-22 |
| NCT05888844 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-10-09 | 2026-12-31 | 2025-12-31 |
| NCT05936359 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | RECRUITING | PHASE1 | 2023-09-25 | 2028-02-29 | 2028-02-29 |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | TERMINATED | PHASE1 | 2023-08-29 | 2024-11-11 | 2024-09-19 |
| NCT05936567 | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-07-31 | 2025-09-05 | 2025-02-28 |
| NCT05906628 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema | COMPLETED | PHASE2 | 2023-07-31 | 2024-12-13 | 2024-07-15 |
| NCT05836324 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 | 2023-07-24 | 2027-01-13 | 2027-01-13 |
| NCT05851443 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | RECRUITING | PHASE2 | 2023-07-11 | 2027-01-31 | 2026-06-15 |
| NCT05764161 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-06-12 | 2025-10-25 | 2024-12-30 |
| NCT05750823 | A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo | COMPLETED | PHASE2 | 2023-04-11 | 2025-03-06 | 2025-03-06 |
| NCT05696392 | The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. | TERMINATED | PHASE4 | 2023-03-16 | 2025-01-22 | 2025-01-22 |
| NCT05755438 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) | COMPLETED | PHASE3 | 2023-03-10 | 2025-08-13 | 2024-10-07 |
| NCT05359692 | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | WITHDRAWN | PHASE2 | 2023-03-01 | 2025-01-11 | 2024-04-20 |
| NCT05620836 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-02-22 | 2026-01-30 | 2025-01-07 |
| NCT05233410 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 | WITHDRAWN | PHASE3 | 2023-01-31 | 2024-09-22 | 2024-04-25 |
| NCT05219864 | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 | WITHDRAWN | PHASE3 | 2023-01-31 | 2024-09-22 | 2024-04-25 |
| NCT05624723 | Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis | COMPLETED | PHASE1 | 2023-01-12 | 2024-02-07 | 2024-02-07 |
| NCT05577182 | Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-01-05 | 2026-08-03 | 2026-08-03 |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | WITHDRAWN | PHASE3 | 2022-12-30 | 2032-08-25 | 2028-12-20 |
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-12-23 | 2027-04-01 | 2026-04-01 |
| NCT05620823 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-12-19 | 2026-01-30 | 2025-02-03 |
| NCT05624710 | A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | COMPLETED | PHASE1 | 2022-12-08 | 2023-06-30 | 2023-06-30 |
| NCT05635838 | Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa | COMPLETED | PHASE2 | 2022-12-07 | 2024-03-14 | 2023-10-19 |
| NCT05593432 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus | COMPLETED | PHASE2 | 2022-11-23 | 2024-02-26 | 2023-10-02 |
| NCT05593445 | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus | COMPLETED | PHASE2 | 2022-11-18 | 2023-12-21 | 2023-09-01 |
| NCT05287113 | Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-11-14 | 2026-07-10 | 2025-03-14 |
| NCT06465433 | Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab | RECRUITING | PHASE2 | 2022-11-08 | 2027-08-29 | 2027-08-29 |
| NCT05456529 | Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis | COMPLETED | PHASE3 | 2022-09-01 | 2024-05-17 | 2024-05-17 |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-07-19 | 2027-11-30 | 2024-07-17 |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | RECRUITING | PHASE1 | 2022-07-05 | 2027-08-31 | 2027-07-27 |
| NCT05267106 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations | TERMINATED | PHASE2 | 2022-05-20 | 2024-12-17 | 2024-12-17 |
| NCT05090891 | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | RECRUITING | PHASE2 | 2022-05-05 | 2032-12-23 | 2025-02-26 |
| NCT05247489 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo | COMPLETED | PHASE2 | 2022-05-05 | 2023-12-19 | 2023-12-19 |
| NCT05253807 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration | COMPLETED | PHASE2 | 2022-04-29 | 2023-08-16 | 2023-08-16 |
| NCT05073458 | Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia | TERMINATED | PHASE3 | 2022-03-15 | 2024-04-29 | 2023-10-17 |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | WITHDRAWN | PHASE3 | 2022-03-11 | 2034-07-07 | 2030-08-15 |
| NCT05101369 | A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550 | COMPLETED | PHASE1 | 2022-01-21 | 2022-03-25 | 2022-03-25 |
| NCT04586244 | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | TERMINATED | PHASE2 | 2022-01-14 | 2024-01-29 | 2024-01-29 |
| NCT05034822 | Study of Ruxolitinib Cream in Children With Atopic Dermatitis | COMPLETED | PHASE1 | 2021-12-16 | 2023-08-07 | 2023-08-07 |
| NCT05099445 | Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis | COMPLETED | PHASE1 | 2021-12-14 | 2023-02-27 | 2023-02-19 |
| NCT05127421 | Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement | COMPLETED | PHASE2 | 2021-11-10 | 2023-09-29 | 2023-08-03 |
| NCT05061693 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis | COMPLETED | PHASE2 | 2021-11-04 | 2024-02-28 | 2023-08-11 |
| NCT05068466 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707 | COMPLETED | PHASE1 | 2021-10-21 | 2022-01-25 | 2022-01-25 |
| NCT04839380 | The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis | COMPLETED | PHASE2 | 2021-10-12 | 2022-11-18 | 2022-11-18 |
| NCT04989387 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | TERMINATED | PHASE1 | 2021-10-04 | 2024-09-19 | 2024-09-19 |
| NCT04809467 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | COMPLETED | PHASE1, PHASE2 | 2021-09-16 | 2024-10-22 | 2024-10-22 |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | TERMINATED | PHASE2 | 2021-09-02 | 2024-03-26 | 2024-03-26 |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma | COMPLETED | PHASE1, PHASE2 | 2021-08-19 | 2024-08-15 | 2024-08-15 |
| NCT04921969 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) | COMPLETED | PHASE3 | 2021-07-19 | 2024-04-08 | 2023-05-10 |
| NCT04629508 | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | COMPLETED | PHASE2 | 2021-07-12 | 2023-08-24 | 2023-08-24 |
| NCT04949191 | The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | TERMINATED | PHASE2 | 2021-07-08 | 2024-04-11 | 2024-04-11 |
| NCT04896385 | A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) | COMPLETED | PHASE2 | 2021-06-23 | 2023-07-10 | 2022-11-17 |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | TERMINATED | PHASE3 | 2021-05-27 | 2024-11-25 | 2023-08-03 |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | TERMINATED | PHASE3 | 2021-05-26 | 2024-08-21 | 2023-08-16 |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-05-11 | 2027-11-01 | 2026-09-01 |
| NCT04818346 | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo | COMPLETED | PHASE2 | 2021-05-06 | 2023-05-24 | 2022-05-24 |
| NCT04831996 | To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. | COMPLETED | PHASE1 | 2021-05-04 | 2022-07-08 | 2022-07-08 |
| NCT04680052 | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-04-15 | 2028-08-09 | 2024-02-23 |
| NCT04831944 | To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. | COMPLETED | PHASE1 | 2021-03-29 | 2022-03-11 | 2022-03-10 |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | TERMINATED | PHASE1 | 2021-03-26 | 2024-08-16 | 2024-08-16 |
| NCT04455841 | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-03-19 | 2027-11-26 | 2025-04-01 |
| NCT04640025 | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-03-10 | 2026-06-22 | 2026-06-22 |
| NCT04279847 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | RECRUITING | PHASE1 | 2021-02-23 | 2026-12-30 | 2025-12-30 |
| NCT04674748 | To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550 | TERMINATED | PHASE1 | 2021-02-03 | 2022-05-13 | 2022-05-13 |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | COMPLETED | PHASE1 | 2021-02-03 | 2024-01-22 | 2024-01-22 |
| NCT04463771 | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-01-26 | 2026-07-10 | 2026-04-14 |
| NCT04472429 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-01-12 | 2026-03-16 | 2024-04-15 |
| NCT04661007 | To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-12-15 | 2026-12-31 | 2026-12-31 |
| NCT04434937 | Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) | COMPLETED | PHASE2 | 2020-09-30 | 2023-10-13 | 2023-02-16 |
| NCT04530344 | Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | COMPLETED | PHASE3 | 2020-09-24 | 2022-11-14 | 2022-11-14 |
| NCT04205812 | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-09-11 | 2026-08-28 | 2023-12-15 |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | COMPLETED | PHASE1 | 2020-09-04 | 2024-11-21 | 2024-08-29 |
| NCT04476043 | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa | COMPLETED | PHASE2 | 2020-08-25 | 2023-08-16 | 2021-12-15 |
| NCT04509700 | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-08-03 | 2027-09-30 | 2027-09-30 |
| NCT04203511 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | WITHDRAWN | PHASE3 | 2020-07-31 | 2025-01-31 | 2023-11-30 |
| NCT04370704 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | COMPLETED | PHASE1, PHASE2 | 2020-07-27 | 2025-08-25 | 2025-08-25 |
| NCT04377620 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | TERMINATED | PHASE3 | 2020-05-24 | 2021-02-26 | 2021-02-26 |
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | TERMINATED | PHASE2 | 2020-05-14 | 2021-04-18 | 2021-04-18 |
| NCT04071366 | A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy | COMPLETED | PHASE2 | 2020-02-07 | 2023-08-22 | 2023-02-23 |
| NCT03978637 | Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation | TERMINATED | PHASE1, PHASE2 | 2020-02-04 | 2023-10-13 | 2023-10-13 |
| NCT03934372 | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2020-01-29 | 2026-01-30 | 2026-01-30 |
| NCT03721965 | Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects | TERMINATED | PHASE1, PHASE2 | 2019-12-31 | 2020-02-17 | 2020-02-17 |
| NCT04003623 | Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) | TERMINATED | PHASE2 | 2019-10-31 | 2020-06-12 | 2020-06-12 |
| NCT03822117 | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | TERMINATED | PHASE2 | 2019-10-17 | 2022-03-29 | 2022-03-29 |
| NCT04057573 | Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) | COMPLETED | PHASE3 | 2019-10-03 | 2021-10-01 | 2021-03-15 |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | TERMINATED | PHASE1, PHASE2 | 2019-09-25 | 2022-04-05 | 2022-04-05 |
| NCT04052425 | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) | COMPLETED | PHASE3 | 2019-09-20 | 2021-10-21 | 2021-03-18 |
| NCT03910530 | A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | COMPLETED | PHASE1 | 2019-07-22 | 2021-12-14 | 2021-12-14 |
| NCT03920839 | INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | WITHDRAWN | PHASE1 | 2019-07-15 | 2019-11-04 | 2019-11-04 |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | TERMINATED | PHASE3 | 2019-06-03 | 2025-07-07 | 2025-07-07 |
| NCT03920852 | A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis | COMPLETED | PHASE1 | 2019-05-30 | 2019-12-26 | 2019-12-26 |
| NCT03780166 | A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris | WITHDRAWN | PHASE2 | 2019-03 | 2020-11 | 2020-11 |
| NCT03627065 | A Study of INCB050465 in Primary Sjögren's Syndrome | COMPLETED | PHASE2 | 2019-02-28 | 2020-01-02 | 2019-12-07 |
| NCT03599713 | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | COMPLETED | PHASE2 | 2019-02-25 | 2024-06-28 | 2022-01-21 |
| NCT03584516 | GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | TERMINATED | PHASE2, PHASE3 | 2019-01-17 | 2023-11-03 | 2023-11-03 |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | COMPLETED | PHASE2 | 2019-01-09 | 2022-06-28 | 2021-04-15 |
| NCT03745638 | Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | COMPLETED | PHASE3 | 2018-12-20 | 2020-12-01 | 2019-12-23 |
| NCT03745651 | TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | COMPLETED | PHASE3 | 2018-12-20 | 2020-11-09 | 2019-11-18 |
| NCT03762447 | A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors | COMPLETED | PHASE1 | 2018-12-10 | 2023-11-17 | 2023-11-17 |
| NCT03688152 | A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma | COMPLETED | PHASE1 | 2018-12-03 | 2020-09-01 | 2020-09-01 |
| NCT03538041 | A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia | COMPLETED | PHASE2 | 2018-11-21 | 2024-04-02 | 2021-08-05 |
| NCT03607487 | A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | COMPLETED | PHASE2 | 2018-10-15 | 2019-08-13 | 2019-08-13 |
| NCT03597295 | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) | COMPLETED | PHASE2 | 2018-10-08 | 2021-11-10 | 2020-06-08 |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | COMPLETED | PHASE1 | 2018-09-24 | 2021-08-18 | 2021-08-18 |
| NCT03627052 | A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis | WITHDRAWN | PHASE2 | 2018-09-20 | 2019-11-13 | 2019-11-13 |
| NCT03522142 | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies | TERMINATED | PHASE1 | 2018-08-27 | 2025-09-10 | 2025-09-10 |
| NCT03589651 | INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2018-08-17 | 2022-11-21 | 2022-11-21 |
| NCT03314922 | A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) | COMPLETED | PHASE1 | 2018-08-02 | 2023-03-09 | 2020-05-05 |
| NCT03569371 | A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | COMPLETED | PHASE2 | 2018-07-17 | 2019-04-22 | 2019-04-22 |
| NCT03424122 | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | COMPLETED | PHASE1 | 2018-07-02 | 2022-06-27 | 2022-06-27 |
| NCT03514407 | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma | TERMINATED | PHASE1 | 2018-06-27 | 2020-06-25 | 2020-06-25 |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | COMPLETED | PHASE1 | 2018-06-18 | 2020-10-07 | 2020-10-07 |
| NCT03347123 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | TERMINATED | PHASE1, PHASE2 | 2018-03-21 | 2021-01-29 | 2021-01-29 |
| NCT03497273 | Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects | COMPLETED | PHASE1 | 2018-03-20 | 2020-02-17 | 2019-11-30 |
| NCT03126019 | A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma | COMPLETED | PHASE2 | 2018-03-14 | 2024-06-07 | 2021-02-26 |
| NCT03361228 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2018-03-01 | 2019-03-30 | 2019-03-30 |
| NCT03320642 | GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease | TERMINATED | PHASE1 | 2018-02-27 | 2022-02-17 | 2021-02-25 |
| NCT03144687 | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis | COMPLETED | PHASE2 | 2018-01-26 | 2021-06-01 | 2020-03-14 |
| NCT03322566 | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | COMPLETED | PHASE2 | 2018-01-09 | 2020-10-16 | 2018-12-13 |
| NCT03348904 | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | TERMINATED | PHASE3 | 2017-12-27 | 2018-05-22 | 2018-05-22 |
| NCT03374488 | Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma | COMPLETED | PHASE3 | 2017-12-22 | 2020-07-23 | 2018-07-27 |
| NCT03144674 | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | COMPLETED | PHASE2 | 2017-12-18 | 2024-05-29 | 2021-01-15 |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | COMPLETED | PHASE2 | 2017-12-15 | 2020-11-09 | 2019-01-10 |
| NCT03342352 | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | WITHDRAWN | PHASE3 | 2017-12-15 | 2018-04-20 | 2018-04-20 |
| NCT03260894 | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | COMPLETED | PHASE3 | 2017-12-07 | 2025-06-04 | 2018-08-22 |
| NCT03361865 | Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) | COMPLETED | PHASE3 | 2017-12-04 | 2020-08-04 | 2018-08-09 |
| NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | ACTIVE_NOT_RECRUITING | PHASE3 | 2017-12-01 | 2025-12-19 | 2018-07-19 |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2017-11-21 | 2022-11-28 | 2022-11-28 |
| NCT03277352 | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | TERMINATED | PHASE1, PHASE2 | 2017-11-21 | 2020-07-01 | 2020-07-01 |
| NCT03235544 | A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor | COMPLETED | PHASE2 | 2017-11-20 | 2024-04-30 | 2024-04-30 |
| NCT03123588 | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | TERMINATED | PHASE2 | 2017-11-14 | 2020-08-03 | 2020-08-03 |
| NCT03241173 | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | COMPLETED | PHASE1, PHASE2 | 2017-10-09 | 2019-09-17 | 2019-09-17 |
| NCT03257644 | A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis | COMPLETED | PHASE1 | 2017-09-21 | 2020-10-07 | 2020-10-07 |
| NCT03235570 | A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) | COMPLETED | PHASE1 | 2017-08-01 | 2020-03-04 | 2020-03-04 |
| NCT03139604 | GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease | COMPLETED | PHASE3 | 2017-07-19 | 2020-07-13 | 2019-05-02 |
| NCT03112603 | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | COMPLETED | PHASE3 | 2017-06-29 | 2022-12-15 | 2020-05-08 |
| NCT03099304 | A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo | COMPLETED | PHASE2 | 2017-06-07 | 2021-09-08 | 2018-09-12 |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | TERMINATED | PHASE1 | 2017-05-25 | 2020-06-10 | 2020-06-10 |
| NCT03085914 | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | COMPLETED | PHASE1, PHASE2 | 2017-05-02 | 2020-07-13 | 2019-01-25 |
| NCT03126110 | Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | COMPLETED | PHASE1, PHASE2 | 2017-04-25 | 2021-11-09 | 2021-11-09 |
| NCT03011372 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) | COMPLETED | PHASE2 | 2017-04-25 | 2024-10-30 | 2024-10-30 |
| NCT03132324 | A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease | TERMINATED | PHASE1 | 2017-04-20 | 2018-10-03 | 2018-10-03 |
| NCT02998476 | A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) | COMPLETED | PHASE2 | 2017-03-02 | 2021-02-05 | 2019-02-22 |
| NCT02959437 | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | TERMINATED | PHASE1, PHASE2 | 2017-02-27 | 2020-03-02 | 2019-02-15 |
| NCT03039114 | Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) | COMPLETED | PHASE1 | 2017-02-15 | 2021-03-30 | 2021-03-30 |
| NCT02718300 | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | TERMINATED | PHASE2 | 2017-02-08 | 2022-04-29 | 2021-01-28 |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) | COMPLETED | PHASE2 | 2017-01-16 | 2022-02-01 | 2022-02-01 |
| NCT02872714 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | COMPLETED | PHASE2 | 2017-01-12 | 2022-02-01 | 2022-02-01 |
| NCT03011892 | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis | COMPLETED | PHASE2 | 2017-01-09 | 2018-03-12 | 2018-01-10 |
| NCT02953678 | A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) | COMPLETED | PHASE2 | 2016-12-30 | 2019-08-14 | 2018-01-31 |
| NCT02760485 | A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | COMPLETED | PHASE1, PHASE2 | 2016-12-29 | 2022-06-06 | 2022-06-06 |
| NCT02917993 | An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2016-12-20 | 2025-12-31 | 2025-12-31 |
| NCT02955940 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | ACTIVE_NOT_RECRUITING | PHASE2 | 2016-11-30 | 2027-09-30 | 2027-09-30 |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | COMPLETED | PHASE2, PHASE3 | 2016-11-28 | 2024-06-21 | 2024-06-21 |
| NCT03059823 | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2016-11-15 | 2024-05-22 | 2024-05-22 |
| NCT02923349 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2016-10-31 | 2019-03-26 | 2019-03-26 |
| NCT02723994 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | ACTIVE_NOT_RECRUITING | PHASE2 | 2016-09-30 | 2026-02-01 | 2026-02-01 |
| NCT02018861 | A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) | COMPLETED | PHASE1, PHASE2 | 2016-09-22 | 2021-04-12 | 2021-04-12 |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | COMPLETED | PHASE1 | 2016-09-14 | 2022-08-15 | 2020-04-30 |
| NCT02752074 | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) | COMPLETED | PHASE3 | 2016-06-21 | 2019-08-16 | 2018-01-08 |
| NCT02697591 | A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2016-06-20 | 2019-12-16 | 2019-12-16 |
| NCT02711137 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | TERMINATED | PHASE1, PHASE2 | 2016-05-18 | 2019-02-13 | 2019-02-13 |
| NCT02712905 | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | TERMINATED | PHASE1, PHASE2 | 2016-05-05 | 2022-04-14 | 2022-04-14 |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | COMPLETED | PHASE1 | 2016-01-25 | 2020-11-20 | 2019-11-07 |
| NCT02587598 | Study of INCB053914 in Subjects With Advanced Malignancies | TERMINATED | PHASE1, PHASE2 | 2015-12-29 | 2020-08-11 | 2020-08-11 |
| NCT02614612 | Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD | COMPLETED | PHASE1 | 2015-12 | 2018-08 | 2016-06 |
| NCT02553330 | A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) | TERMINATED | PHASE2 | 2015-11-18 | 2017-10-03 | 2017-10-03 |
| NCT02559492 | Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors | TERMINATED | PHASE1 | 2015-11 | 2019-08-18 | 2018-09-10 |
| NCT02456675 | INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma | TERMINATED | PHASE2 | 2015-06 | 2016-12-16 | 2016-12-16 |
| NCT02431260 | An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies | TERMINATED | PHASE1, PHASE2 | 2015-04-14 | 2018-01-31 | 2018-01-31 |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | TERMINATED | PHASE1, PHASE2 | 2015-02-27 | 2021-12-17 | 2021-12-17 |
| NCT02318277 | A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | COMPLETED | PHASE1, PHASE2 | 2015-01-05 | 2020-10-16 | 2019-08-28 |
| NCT01641107 | Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. | COMPLETED | PHASE2 | 2014-12-04 | 2021-09-30 | 2020-04-24 |
| NCT02355431 | Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | WITHDRAWN | PHASE2 | 2014-12 | 2015-09 | 2015-09 |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | COMPLETED | PHASE1, PHASE2 | 2014-11-26 | 2020-06-16 | 2020-06-16 |
| NCT02298153 | A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110) | TERMINATED | PHASE1 | 2014-11 | 2017-11-08 | 2017-11-08 |
| NCT02265510 | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | TERMINATED | PHASE1, PHASE2 | 2014-09-10 | 2019-02-27 | 2019-02-27 |
| NCT02257619 | Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | TERMINATED | PHASE2 | 2014-09 | 2016-04 | 2016-02 |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | COMPLETED | PHASE1, PHASE2 | 2014-07-17 | 2020-11-06 | 2018-11-26 |
| NCT02119663 | A Study of Ruxolitinib in Pancreatic Cancer Patients | TERMINATED | PHASE3 | 2014-06 | 2016-10 | 2016-02 |
| NCT02120417 | A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | TERMINATED | PHASE2 | 2014-05 | 2017-01 | 2016-02 |
| NCT02151474 | INCB047986 in Rheumatoid Arthritis | TERMINATED | PHASE2 | 2014-05 | 2014-08 | 2014-08 |
| NCT02117479 | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | TERMINATED | PHASE3 | 2014-03 | 2016-12 | 2016-02 |
| NCT02119676 | Study of Ruxolitinib in Colorectal Cancer Patients | TERMINATED | PHASE2 | 2014-03 | 2016-12 | 2016-02 |
| NCT02119650 | Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer | TERMINATED | PHASE2 | 2014-02-11 | 2016-06-21 | 2016-02-11 |
| NCT02093429 | Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS) | TERMINATED | PHASE1, PHASE2 | 2014-01 | 2014-09 | 2014-09 |
| NCT01929941 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | TERMINATED | PHASE1 | 2013-09 | 2014-08 | 2014-08 |
| NCT01905813 | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2013-06-30 | 2026-04-17 | 2026-04-17 |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2013-06 | 2016-03 | 2016-02 |
| NCT01822756 | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | TERMINATED | PHASE1 | 2013-04 | 2016-08 | 2015-09 |
| NCT01685255 | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | TERMINATED | PHASE2 | 2012-08 | 2014-10-23 | 2014-10-23 |
| NCT01633372 | An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | COMPLETED | PHASE2 | 2012-07-16 | 2021-06-29 | 2013-12-31 |
| NCT01634087 | A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis | COMPLETED | PHASE2 | 2012-06 | 2013-02 | 2013-01 |
| NCT01632904 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | COMPLETED | PHASE3 | 2012-06 | 2016-05 | 2014-03 |
| NCT01626573 | A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis | COMPLETED | PHASE2 | 2012-03 | 2013-10 | 2013-07 |
| NCT01604889 | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | TERMINATED | PHASE1, PHASE2 | 2012-03 | 2016-12-27 | 2016-12-27 |
| NCT01445769 | Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis | COMPLETED | PHASE2 | 2011-09 | 2013-04 | 2013-03 |
| NCT01423604 | Study of Ruxolitinib in Pancreatic Cancer Patients | COMPLETED | PHASE2 | 2011-07 | 2016-11 | 2013-06 |
| NCT01348490 | Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) | COMPLETED | PHASE2 | 2011-06-15 | 2018-12-19 | 2018-12-19 |
| NCT01317875 | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) | COMPLETED | PHASE1 | 2011-03-31 | 2019-12-31 | 2019-12-31 |
| NCT01340651 | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | COMPLETED | PHASE2 | 2011-03 | 2012-07 | 2012-07 |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | COMPLETED | PHASE3 | 2010-10-27 | 2018-02-09 | 2014-01-15 |
| NCT01254136 | Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer | TERMINATED | PHASE1, PHASE2 | 2010-10 | 2011-10 | 2011-09 |
| NCT01195311 | A Dose-escalation Study in Subjects With Advanced Malignancies | COMPLETED | PHASE1 | 2010-07 | 2013-07 | 2013-05 |
| NCT01072266 | A Dose-escalation Study in Subjects With Advanced Malignancies | COMPLETED | PHASE1 | 2010-01 | 2013-01 | 2012-07 |
| NCT00952289 | COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial | COMPLETED | PHASE3 | 2009-08 | 2015-10 | 2010-11 |
| NCT00902486 | INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs | COMPLETED | PHASE2 | 2009-05 | 2010-07 | 2010-06 |
| NCT00778700 | A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis | COMPLETED | PHASE2 | 2008-10-28 | 2009-06-26 | 2009-06-26 |
| NCT00726232 | Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia | TERMINATED | PHASE2 | 2008-08-20 | 2018-08-20 | 2010-06-20 |
| NCT00698230 | Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics | COMPLETED | PHASE2 | 2008-05 | 2009-05 | 2009-04 |
| NCT00698789 | Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes | TERMINATED | PHASE2 | 2008-05 | 2009-06 | 2009-02 |
| NCT00639002 | A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | COMPLETED | PHASE2 | 2008-03 | 2010-07 | 2010-07 |
| NCT00638378 | Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | TERMINATED | PHASE2 | 2008-02 | 2009-01 | 2009-01 |
| NCT00550043 | A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis | COMPLETED | PHASE2 | 2007-10 | 2008-09 | 2008-09 |
| NCT00617994 | Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis | COMPLETED | PHASE2 | 2007-08-31 | 2009-05-31 | 2009-04-30 |
| NCT00864175 | Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer | TERMINATED | PHASE1, PHASE2 | 2007-07 | 2011-10 | 2011-06 |
| NCT00509899 | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | COMPLETED | PHASE1, PHASE2 | 2007-06 | 2017-02 | 2007-12 |
| NCT00820950 | A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis | COMPLETED | PHASE2 | 2007-05-31 | 2009-04-30 | 2009-01-31 |
| NCT00478322 | Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects | COMPLETED | PHASE2 | 2007-04 | 2008-02 | 2007-11 |
| NCT00398619 | A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes | COMPLETED | PHASE1 | 2006-11 | 2007-03 | 2007-03 |
| NCT00393120 | Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients | COMPLETED | PHASE2 | 2006-10 | 2007-09 | 2007-09 |
| NCT00300573 | Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs | TERMINATED | PHASE2 | 2006-04 | 2006-04 | |
| NCT00820560 | Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors | COMPLETED | PHASE1 | 2005-01 | 2009-01 | 2009-01 |